AP
OMED

AlpInvest Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

AlpInvest Partners’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-22,450
Closed -$489K – 29
2014
Q4 		$489K Buy
+22,450
New +$460K 1.21% 12

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Apex Capital Orinda, California $938M AUM 4.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlpInvest Partners's OMED Position: Q1 2015 in Review

AlpInvest Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2015, closing a stake of 22,450 shares — an estimated $489K sold.

AlpInvest Partners first reported a position in OMED in Q4 2014 and held it in 1 quarter. The position peaked at $489K in Q4 2014. 78 funds tracked by Wall St. Rank hold OMED as of Q1 2015.

  • AlpInvest Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • AlpInvest Partners sold 22,450 OncoMed Pharmaceuticals, Inc. shares in Q1 2015, an estimated $489K.
  • AlpInvest Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • AlpInvest Partners's OncoMed Pharmaceuticals, Inc. position peaked at $489K in Q4 2014.
  • 78 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2015.

Based on AlpInvest Partners's 13F filing for Q1 2015, filed 15 May 2015.